Se Jin Jang
Overview
Explore the profile of Se Jin Jang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
229
Citations
7797
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ahn B, Kim D, Ji W, Chun S, Lee G, Jang S, et al.
Lung Cancer
. 2025 Feb;
201:108445.
PMID: 39954349
Background: The clinicopathologic and therapeutic significance of SMARCA4 mutation in non-small cell lung carcinoma (NSCLC) remains unclear. Methods: We retrieved 575 NSCLC cases from the clinical target sequencing cohort (N...
2.
Song K, Choi S, Kim K, Hwang H, Chang E, Park J, et al.
Nat Commun
. 2024 Nov;
15(1):10164.
PMID: 39580524
Non-small cell lung cancer (NSCLC) is histologically classified into lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LSCC). However, some tumors are histologically ambiguous and other pathophysiological features or microenvironmental...
3.
Park J, Jo J, Kim S, Redon C, Aladjem M, Seo Y, et al.
Sci Rep
. 2024 Nov;
14(1):27487.
PMID: 39523440
Neuroendocrine tumor (NET) is a rare malignant tumor, notably small cell lung cancer (SCLC), a type of lung neuroendocrine tumor, which has a survival rate of less than 7%. Although...
4.
Kim H, Kim W, Kim M, Ko N, Jin M, Jung H, et al.
Cancer Immunol Immunother
. 2024 Oct;
73(12):260.
PMID: 39382668
Thyroid immune-related adverse events (irAEs) are associated with programmed cell death protein 1 (PD-1) blockade efficacy in non-small cell lung cancer (NSCLC). However, their independence from PD-L1 expression and quantitative...
5.
Ahn B, Jang S, Hwang H
Am J Clin Pathol
. 2024 Sep;
163(2):258-265.
PMID: 39267255
Objectives: ROS-1 immunohistochemistry (IHC) is a common method for screening ROS1 fusion in the clinical management of non-small cell lung cancer. The interpretation criteria for ROS-1 SP384 IHC, however, remain...
6.
Chang E, Kim S, Hwang H, Song K, Kim K, Kim M, et al.
Clin Transl Med
. 2024 Aug;
14(8):e1796.
PMID: 39148143
No abstract available.
7.
Lee B, Hwang H, Jang S, Oh S, Kim M, Choi C, et al.
Thorac Cancer
. 2024 Jun;
15(21):1638-1645.
PMID: 38886915
Introduction: Electromagnetic navigation bronchoscopy (ENB) and radial probe endobronchial ultrasound (RP-EBUS) are essential bronchoscopic procedures for diagnosing peripheral lung lesions. Despite their individual advantages, the optimal circumstances for their combination...
8.
Kim P, Hwang H, Choi G, Sung H, Ahn B, Uh J, et al.
Sci Rep
. 2024 Mar;
14(1):6366.
PMID: 38493247
This study aimed to develop a deep learning (DL) model for predicting the recurrence risk of lung adenocarcinoma (LUAD) based on its histopathological features. Clinicopathological data and whole slide images...
9.
Lee S, Jeong H, Kim D, Jang S, Kim S, Yoon S, et al.
Cancer Res Treat
. 2024 Jan;
56(3):774-784.
PMID: 38291744
Purpose: Exon 20 insertion mutations (E20ins) in epidermal growth factor receptor (EGFR) or human epidermal growth factor receptor 2 (HER2) in non-small cell lung cancer (NSCLC) patients has become more...
10.
Lee B, Lee C, Moon H, Jo S, Jang S, Suh Y
Cells
. 2023 Dec;
12(24).
PMID: 38132178
The effect of agonists on AMP-activated protein kinase (AMPK), mainly metformin and phenformin, has been appreciated in the treatment of multiple types of tumors. Specifically, the antitumor activity of phenformin...